|
|
Post by uvula on Jul 4, 2014 15:51:04 GMT -5
People keep taking about how marketing will cost 100s of millions.
Before the internet existed a company had to hire 1000s of sales reps to individually inform and train the doctors and the company had no direct access to potential patients except for placing expensive advertisements in print media and advertising on TV. This took a huge workforce and a ton of money. Big Pharma still operates this way because they are used to it and everyone wants to preserve their jobs.
Now that we have email, blogs, facebook, youtube, message boards, etc., why do we still have to do business this way? Can't Mannkind just team up with Amazon, let patients order on-line, and ship the stuff to doctor's offices? I realize it will be more difficult than this but I still don't see why Mannkind would need to get their own huge sales force.
|
|
|
|
Post by babaoriley on Jul 4, 2014 15:57:53 GMT -5
Greasing palms requires personal contact?
|
|
|
|
Post by otherottawaguy on Jul 4, 2014 19:33:56 GMT -5
Maybe they could set it up like a MLM, you get someone to subscribe and you get a months supply, only need to get 12 a year on board and your riding for free. If you are getting more than 48 a year signing up, they hired you as a sales rep and get cashed out at 5-10% of the revenue stream your generating...but only while the current insulin supply lasts, its not like they won't have the margin if retail is being bypassed and the "partner" ta boot.
OOG |
|
|
|
Post by jpg on Jul 4, 2014 23:56:50 GMT -5
Greasing palms requires personal contact? There are no or very few MDs being 'greased' in the US anymore. They don't even give pens anymore... JPG |
|
|
|
Post by uvula on Jul 7, 2014 10:13:52 GMT -5
Cool. Forbes is listening to me. Someone else here posted a link to this article" www.forbes.com/sites/greatspeculations/2014/02/06/novo-hiring-new-reps-now-they-need-something-to-sell/"Although pharma reps hate to hear this, the reality is their job function can be easily and more cost effectively performed by an automated or virtual system. This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way. The days of pharma reps sitting with physicians reviewing the latest study data are over, the simple fact is if a physician wants information on any drug the fastest, easiest way to get it is to surf the net. Add in the fact that either by law or by cost concerns also over are the days when reps can leave behind drug samples." |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 7, 2014 11:49:53 GMT -5
In Afrezza's case, "This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way.
", probably does not apply?
|
|
|
|
Post by uvula on Jan 13, 2016 23:05:05 GMT -5
About time mnkd starts listening to me!
|
|
|
|
Post by od on Jan 13, 2016 23:19:56 GMT -5
Cool. Forbes is listening to me. Someone else here posted a link to this article" www.forbes.com/sites/greatspeculations/2014/02/06/novo-hiring-new-reps-now-they-need-something-to-sell/"Although pharma reps hate to hear this, the reality is their job function can be easily and more cost effectively performed by an automated or virtual system. This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way. The days of pharma reps sitting with physicians reviewing the latest study data are over, the simple fact is if a physician wants information on any drug the fastest, easiest way to get it is to surf the net. Add in the fact that either by law or by cost concerns also over are the days when reps can leave behind drug samples." 2 years old biased commentary - get over yourself. Novo up 33% since article published. |
|
|
|
Post by mnkdmorelong on Jan 14, 2016 6:24:42 GMT -5
People keep taking about how marketing will cost 100s of millions. Before the internet existed a company had to hire 1000s of sales reps to individually inform and train the doctors and the company had no direct access to potential patients except for placing expensive advertisements in print media and advertising on TV. This took a huge workforce and a ton of money. Big Pharma still operates this way because they are used to it and everyone wants to preserve their jobs. Now that we have email, blogs, facebook, youtube, message boards, etc., why do we still have to do business this way? Can't Mannkind just team up with Amazon, let patients order on-line, and ship the stuff to doctor's offices? I realize it will be more difficult than this but I still don't see why Mannkind would need to get their own huge sales force. Five years from now when docs, patients and insurance are fully comfortable with Afrezza, an Amazon model will work. Matt recited a story last night of an endocrinologist who was invited to a SNY panel meeting. This endo is a diabetic who tried Afrezza and gave up. But once he heard how the drug should be used, he went back on and saw the benefits. The point of this anecdote is that using Afrezza is not natural when coming from RAA. The learning curve is steep and each patient must find his or her center. All this cannot be done on Amazon. Without a US salesforce, the growth of Afrezza in the US will be slow. |
|
|
|
Post by sf1981 on Jan 14, 2016 7:03:13 GMT -5
It would be awesome if somebody can find that story. If I understood correctly, that doc wrote an article about his experience. Or has anyone already found it? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 14, 2016 7:30:07 GMT -5
|
|
|
|
Post by mnkdmorelong on Jan 14, 2016 7:34:01 GMT -5
It would be awesome if somebody can find that story. If I understood correctly, that doc wrote an article about his experience. Or has anyone already found it? Yes he wrote an article but I have not seen it yet. Here we have an expert on diabetes management and could not figure out how to use Afrezza for his situation. The average patient would probably struggle more. This anecdote, as Matt said, explains in part why there were so many drop-outs under SNY. It also highlights how difficult it will be going forward. Perhaps the diabetes centers is the answer. If each had a Sam Finta on staff 24/7 (LOL), the drop out rate will be much smaller. To truly extract the benefit of Afrezza, the diabetic must be willing to let BG drop to near hypo levels. The secret sauce is that with RAA, the hypo goes on and could be dangerous. However with Afrezza, the insulin goes away and the hypo stops. Long term, near hypo conditions lead to lower HbA1c. CGM makes this easy. Without monitoring, it is an adventure. |
|
|
|
Post by sf1981 on Jan 14, 2016 7:35:38 GMT -5
|
|
